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This analysis found the ARFs for OS to be ≥87 days from 
surgery to end of RT (HR 3.3; p=0.0025 vs <87 days) and ECE 
(HR 2.6 vs no ECE; p=0.0133). Adverse events did not differ 
between the groups. 
Conclusions: The present analysis has shown that OTT can be 
an important factor in DFS. OTT of 87 days is challenging and 
requires careful coordination of procedures and disciplines 
between surgery and adjuvant therapy, as well as minimizing 
treatment delays during RT. Our findings suggest that 
treatment completed within as short a timeframe as possible 
appears to be associated with longer DFS and that this should 
be a goal. Further studies are needed to confirm these 
findings.  
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Purpose/Objective: To develop a methodology for using FDG 
PET/CT in adaptive DPBN in locally advanced head and neck 
squamous cell carcinoma (HNSCC) patients. Issues related to 
noise in PET and robustness against geometric errors are 
addressed. 
Materials and Methods: Five patients with locally advanced 
HNSCC scheduled for chemo-radiotherapy were imaged with 
FDG-PET/CT at baseline and after 5, 10 and 15 fractions of 
RT (2 patients were re-imaged only twice). The GTVPET was 
segmented with a gradient-based method. A double median 
filter reduces the impact of noise in the conversion from PET 
uptake to prescribed dose. Filtered FDG uptake values were 
linearly converted into a voxel-by-voxel prescription from 70 
(median uptake) to 86 Gy (highest uptake). To be robust 
against geometrical uncertainties, a PTVPET was obtained by 
applying a dilation of 2.5 mm to the entire prescription. 
Seven iso-uptake thresholds led to 7 sub-levels compatible 
with the Tomotherapy HiArt® Treatment Planning System. 
Planning aimed to deliver a median dose of 56 Gy and 70 Gy 
in 35 fractions on the elective and therapeutic PTVs, 
respectively. Plan quality was assessed with quality-volume 
histogram (QVH) and quality factor (QF, objective: <5%). For 
organs at risk (OARs), DVH constraints were the following: 
Dmean < 26-30 Gy for parotid glands, D2 < 30 Gy for PRV spinal 
cord and brain stem. At each time point, plans were 
generated using a 1 cm collimator width with a total of 3 to 4 
plans for each patient. Deformable image registration was 
used for automatic propagation of volumes of interest and 
dose summation of the 3 or 4 treatment plans (MIM vista®) 
(see figure). Finally, to simulate a treatment that is adaptive 
to anatomical evolution seen at CT but blind to changes in 
the PET signal, the pre-treatment dose map was deformed 
and assessed with QVHs on each per-treatment CT scan after 
non-rigid image registration. 
 
 
 
Results: GTVPET segmentations were performed successfully 
until week 2 of RT but failed in 2 patients at week 3. QVH 
analysis showed high conformity for all plans (mean VQ=0.95 
93%; mean VQ=1.05 3.9%; mean QF 2.2%) demonstrating 
feasibility of the treatment. Good OAR sparing was achieved 
while keeping high plan quality (see table). When comparing 
biologic/anatomic adaptation versus only anatomic 
adaptation, QFs were improved in all cases (range 0.8 – 3.7%) 
with a median value of 2.1% and 4.7% for the biological 
adaptive and anatomic only adaptive strategy, respectively. 
 
Conclusions: Our results show that adaptive FDG-PET-based 
escalated dose painting in patients with locally advanced 
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HNSCC is feasible while respecting strict dose constraints to 
OARs. By correcting for morphological and biological tumor 
changes during RT, higher conformity is ensured between the 
FDG uptake and the dose distributions. Clinical studies must 
be conducted to evaluate the acute and chronic toxicities 
and the tumor response of such a strategy.  
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Purpose/Objective: Current treatment of advanced cancer of 
the head and neck is unsatisfactory in terms of outcome and 
the toxicity of current treatments are severe. Phase III 
clinical trials have shown that hyperthermia (heating in the 
range of 40-44°C for one hour) is a potent sensitizing agent 
of radiotherapy, which is achieved without additional toxicity 
[1-3]. To enable heat-sensitization also in target regions at 
deep locations, we developed the HYPERcollar and showed in 
45 patients that inducing hyperthermia in tumors located 
deeply and laterally in the head and neck region is feasible 
and has potential. Over the years, we further introduced an 
adaptive hyperthermia strategy based on electromagnetic 
field simulations. In this study, we analyze the HYPERcollar3D 
that is a redesigned version of the HYPERcollar aimed at 
improving heating quality, heating reproducibility and patient 
comfort.  
Materials and Methods: In the HYPERcollar3D, patient 
comfort and treatment accuracy/stability are improved by 
splitting the waterbolus functions into a stable outer part and 
a patient conformal inner part. Patient positioning according 
to the CT resembles that of radiotherapy and is obtained by 
immobilization and a laser alignment procedure. Based on a 
mechanical redesign, we performed parameter studies using 
electromagnetic simulator SEMCAD-X (v. 14.8.6) to 
investigate further improvement by increasing the number of 
antennas and their locations.  
Results: The simulation studies showed that higher number of 
antennas, and their repositioning, allows for a substantially 
improved treatment quality. All improvements combined 
enable a predicted reduction of hotspot importance 
prominence (hot-spot target quotient (HTQ)) by 32%. 
Combining all systems improvements, simulations predict 
that a doubling of the clinically applied power to the target 
can be achieved. After clinical introduction, two patients 
(nasopharynx ca. and a neck node metastasis) have been 
treated with the HYPERcollar3D. Validation of heating 
performance by invasive thermometry in the tumor proved 
not possible but, in both patients, the scheduled treatments 
of 75 minutes could be completed using a mean applied 
power of 350-400W. In addition, the estimated SAR based on 
the realtime measured powers/phases of the signals was 
90W-200W/kg, which is beyond the long term average 
applied SAR using the conventional HYPERcollar, i.e. 75W/kg.  
Conclusions: Although the improvement still has to be 
validated by invasive temperature measurements in the 
tumor, these results are very reassuring that the 
HYPERcollar3D will provide a significant improvement in 
treatment quality. Hyperthermia is currently used as a 
standard addition to radiotherapy for patients that are re-
irradiated. A protocol for a clinical study in primary tumors is 
being finalized.  
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Purpose/Objective: To identify patterns of long-term, 
radiation-induced swallowing dysfunction after completion of 
definitive radiotherapy with or without chemotherapy (RT or 
CRT) and to determine which factors could explain these 
patterns over time. 
Materials and Methods: The study population consisted of 
238 consecutive head and neck cancer patients treated with 
RT or CRT. The primary endpoint was ≥ grade 2 swallowing 
dysfunction at 6, 12, 18 and 24 months after treatment. 
Cluster analysis was used to identify different patterns over 
time. The degree of swallowing dysfunction at baseline and 
at all subsequent time points (at 6, 12, 18 and 24 months) 
were considered for cluster modeling on the basis of their 
contribution to characterizing the patterns of late radiation-
induced swallowing dysfunction. The differences between the 
dose-volume histograms (DHVs) of the swallowing organs at 
risk for each pattern were determined by using dose maps. 
Results: The cluster analysis revealed five patterns of long-
term, radiation-induced swallowing dysfunction: low 
persistent, moderate persistent, severe persistent, transient 
and progressive (Figure 1). Patients with high dose to the 
upper pharyngeal, laryngeal and lower pharyngeal region had 
the highest risk of severe persistent swallowing dysfunction. 
